Dr. Monk on the Mechanism of Action of VB-111 in Ovarian Cancer

Bradley Monk, MD, FACOG, FACS, a gynecologic oncologist at Arizona Oncology, discusses the mechanism of action of VB-111 in patients with ovarian cancer.

VB-111 is a targeted anticancer viral gene therapy that is based on a non-replicating, non-integrating adenovirus 5 vector that contains a transgene expressed solely in angiogenic blood vessels, according to Monk.

The agent has a dual mechanism of action, Monk says. The agent targets endothelial cells, which causes vascular disruption and results in tumor starvation, and induces immune response through local inflammation, Monk concludes.